ERBB2
ERBB2 (HER2) is a specialized receptor tyrosine kinase that serves as the universal multiplier for cellular growth signals. Unlike its relatives, it has no ligand of its own but is permanently "primed" to pair with other receptors, forming the most potent signaling units in the cell; its amplification is the defining driver of aggressive HER2-positive breast and gastric cancers.
Key Takeaways
- •HER2 is a "promiscuous" receptor that is always ready to pair up and multiply growth signals from other receptors.
- •It has no known ligand (key); it is a permanent "lock" that is always open for its partners.
- •HER2 amplification occurs in ~20% of breast cancers, where it drives rapid, aggressive tumor growth.
- •The heart depends on HER2 for repair; this is why some HER2 cancer drugs can cause heart-related side effects.
- •The development of Trastuzumab (Herceptin) remains one of the greatest success stories in targeted cancer therapy.
Basic Information
- Gene Symbol
- ERBB2
- Full Name
- Erb-B2 Receptor Tyrosine Kinase 2
- Also Known As
- HER2NEUNGLTKR1
- Location
- 17q12
- Protein Type
- Receptor Tyrosine Kinase
- Protein Family
- ERBB family
Related Isoforms
The canonical full-length receptor involved in signal multiplication.
A truncated, constitutively active fragment created by proteolytic cleavage.
Key SNPs
Associated with altered risk and progression in breast and gastric cancers.
Investigated as a potential modifier of response to anti-HER2 therapies.
Activating mutation found in lung and breast cancers; confers sensitivity to specific TKIs.
Acquired mutation conferring resistance to lapatinib but sensitive to newer inhibitors.
Common in HER2-mutant non-small cell lung cancer; leads to constitutive activation.
Overview
ERBB2, more commonly known as HER2 (Human Epidermal Growth Factor Receptor 2), is a unique member of the ERBB family of receptor tyrosine kinases. While its relatives (like EGFR) must wait for a growth factor "key" to bind before they can activate, HER2 is different: its extracellular structure is permanently "locked" in an open, active position. It acts as the universal preferred partner for all other members of its family.
When HER2 pairs with another receptor—especially HER3—it forms a powerhouse signaling unit that is far more potent than any single receptor alone. This complex triggers the PI3K/AKT survival pathway with extreme efficiency. Because of this role as a signal multiplier, even a small increase in the number of HER2 receptors can lead to the uncontrolled growth and survival that characterizes HER2-positive malignancies.
Conceptual Model
A simplified mental model for the pathway:
When HER2 is overexpressed, the growth engine runs at full speed without needing a key.
Core Health Impacts
- • Cardiac Repair: Absolutely essential for the repair and survival of heart muscle cells under stress.
- • Epithelial Growth: Master regulator of division in skin, breast, and gastrointestinal tissues.
- • Oncogenesis: Primary driver of malignancy when the gene is duplicated or amplified.
- • Neural Development: Influences the migration of neural cells and the formation of the myelin sheath.
- • Hormone Resistance: Can provide a "bypass" signal that makes breast cancers resistant to estrogen blockers.
Protein Domains
Dimerization Arm
The "handshake" region that is constitutively exposed in HER2, unlike other ERBBs.
Kinase Domain
The internal engine that flips the metabolic and survival switches of the cell.
Transmembrane
The anchor segment where specific mutations can cause spontaneous activation.
Upstream Regulators
Heterodimerization Activator
HER2 is activated by pairing with EGFR, HER3, or HER4 after they bind their ligands.
Gene Amplification Activator
High receptor density leads to spontaneous dimerization and ligand-independent signaling.
EGFR (ERBB1) Activator
Frequently forms heterodimers with HER2 to create a potent MAPK signaling unit.
HER3 (ERBB3) Activator
The most potent partner for PI3K activation; provides the platform for HER2 to signal.
Src Kinase Activator
Can phosphorylate HER2 to amplify its signaling and promote invasive behavior.
ADAM Proteases Activator
Cleave the extracellular domain to produce the constitutively active p95 fragment.
Downstream Targets
PI3K / AKT Pathway Activates
The primary survival and metabolic pathway activated through HER2/HER3 dimers.
MAPK / ERK Pathway Activates
Drives cell proliferation and cell cycle progression downstream of HER2.
JAK / STAT Pathway Activates
Mediates survival signals and contributes to immune evasion in tumor cells.
PLC-gamma 1 Activates
Triggers calcium signaling and PKC activation, influencing cell motility and invasion.
Cyclin D1 Activates
Upregulated by HER2 signaling to promote entry into the cell division cycle.
mTORC1 Activates
Integrates HER2-derived signals to coordinate protein synthesis and growth.
Role in Aging
HER2 signaling is a vital component of tissue maintenance, but its decline or dysregulation is a key feature of the aging process, especially in the heart and gut.
Cardiac Resilience
HER2 is essential for heart muscle repair; its activity declines with age, increasing vulnerability to failure.
Senescence Bypass
Overactive HER2 can allow damaged cells to bypass the aging "stop sign" of senescence, leading to cancer.
Proteostasis
Chronic HER2 activation of the mTOR pathway suppresses the cells natural cleaning system (autophagy).
Stem Cell Niche
Declining HER2/HER3 signaling in the gut reduces the regenerative capacity of the intestinal lining.
Cardiotoxicity
Older patients are at higher risk for heart damage when treated with HER2-blocking drugs.
Inflammaging
Persistent growth signaling through the ERBB family can exacerbate the secretory profile of senescent cells.
Disorders & Diseases
HER2+ Breast Cancer
Characterized by gene amplification at 17q12, leading to 100x more HER2 protein and aggressive growth.
Gastric Cancer
A significant subset of stomach and esophageal cancers overexpress HER2 and respond to targeted drugs.
HER2-mutant NSCLC
A distinct form of lung cancer driven by mutations (not amplification) in the HER2 gene.
Cardiomyopathy
Loss of HER2 signaling in heart cells can lead to reduced contraction strength and heart failure.
Schizophrenia Risk
Genetic variants in the ERBB family (including HER2) are associated with altered brain connectivity.
Interventions
Supplements
May reduce HER2 expression by altering the lipid rafts where the receptor is located.
Catechin reported to inhibit HER2 tyrosine kinase activity and promote cell death in research.
Studied for its ability to downregulate HER2 and inhibit its downstream survival cascades.
Exerts anti-proliferative effects that may help balance growth factor signaling in epithelial cells.
Soy isoflavone that can interfere with the signaling of multiple receptor tyrosine kinases.
Lifestyle
Lowering adiposity reduces systemic insulin and IGF-1, which can "muffle" HER2 signaling.
Improves metabolic health and cardiac resilience, protecting the heart from growth factor decline.
Excessive alcohol is a risk factor for breast cancer and can influence RTK-related pathways.
Reduces the systemic inflammation that drives compensatory growth factor activation.
Medicines
Monoclonal antibody that blocks HER2 cleavage and tags cancer cells for immune destruction.
Antibody that specifically blocks the HER2 dimerization arm, preventing it from pairing.
An antibody-drug conjugate that uses HER2 as a "Trojan Horse" to deliver chemo inside the cell.
A dual small-molecule inhibitor that blocks the internal kinase switch of both EGFR and HER2.
A highly selective HER2 inhibitor that can cross the blood-brain barrier to treat metastases.
Lab Tests & Biomarkers
Diagnostic Testing
Immunohistochemistry to measure protein density on the cell surface (target: 3+).
Fluorescence In Situ Hybridization to confirm gene amplification at the DNA level.
Safety Monitoring
Mandatory heart scan to monitor LVEF for patients on HER2-targeted therapies.
Experimental test measuring the "shed" portion of the receptor in the blood.
Pathway Context
Research readouts showing the activity of the survival pathways driven by HER2.
Hormonal Interactions
Estrogen Crosstalk Partner
Estrogen and HER2 pathways often bypass each other to resist hormone-blocking drugs.
Insulin Metabolic Amplifier
High insulin provides extra "fuel" for the growth cascades initiated by HER2.
IGF-1 Synergistic Driver
Works with HER2 to provide a powerful dual-signal for cell survival and division.
Cortisol Stress Regulator
Can influence the expression of receptors and the inflammatory microenvironment.
Deep Dive
Network Diagrams
The HER2 Pairing Hub
How HER2 Drugs Work
The “Promiscuous” Partner: Why HER2 is Essential
To understand why HER2 is so dangerous in cancer, you have to understand its unique structure. In the ERBB family, most receptors are like a closed book that only opens when a ligand (key) binds to them.
- Always Open: HER2 is synthesized in the “open” position. It doesn’t need a key to reveal its dimerization arm. It is always roaming the cell membrane, ready to “shake hands” with any other ERBB receptor that has been activated by a growth factor.
- The HER3 Synergy: Its most critical relationship is with HER3. While HER3 cannot signal on its own, it has many docking sites for survival proteins (PI3K). When HER2 pairs with HER3, it provides the “engine” (kinase) that HER3 lacks, creating the most potent survival signal known in cell biology.
Targeted Therapy: The Herceptin Revolution
The discovery of HER2 led to the creation of Trastuzumab (Herceptin), the drug that proved cancer could be treated by targeting specific genetic errors rather than just using broad chemotherapy.
- Blocking the Shedding: HER2 has a tendency to have its external head cut off by enzymes, leaving a “headless” active stump (p95) inside the cell. Trastuzumab prevents this cutting.
- Immune Recruitment: The drug also acts like a “flag” for the immune system. It sticks to the cancer cell and tells Natural Killer (NK) cells to come and destroy it. This dual action—blocking the signal and calling the police—is why it is so effective.
The Heart Connection: A Vital Safety Warning
A critical lesson from HER2 biology is that growth signaling is not just for cancer; it is also for repair.
In the heart, HER2 signaling is the primary way that cardiomyocytes (heart muscle cells) survive stress and repair minor damage. This is why patients on HER2-blocking drugs must be carefully monitored. If you turn off HER2 too completely, the heart loses its “mechanic,” leading to a temporary weakening of the heart muscle. Understanding this link has led to safer protocols that protect the heart while still fighting the cancer.
Practical Note: Cardiac Safety and HER2
Heart Monitoring is Mandatory. Because HER2 is needed for heart repair, anyone taking HER2 blockers must get regular heart scans.
HER2-Low Status. Newer drugs can now help patients with even low levels of HER2, changing how we classify these cancers.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The foundational study that identified HER2 as a key driver and biomarker in breast cancer.
Pivotal trial demonstrating the life-saving efficacy of Trastuzumab (Herceptin).
Established the efficacy of the new "Trojan Horse" ADC approach for HER2 cancers.
Seminal review detailing why HER2 is the preferred partner for all other family members.